Tcr2 Therapeutics Inc (TCRR) falls 3.65% for July 26

Equities Staff  |

Today, Tcr2 Therapeutics Inc Inc’s (NASDAQ: TCRR) stock fell $0.48, accounting for a 3.65% decrease. Tcr2 opened at $13.14 before trading between $13.43 and $12.61 throughout Monday’s session. The activity saw Tcr2’s market cap fall to $484,281,516 on 329,806 shares -above their 30-day average of 312,226.

About Tcr2 Therapeutics Inc

TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2's proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company's lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company's lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).

Visit Tcr2 Therapeutics Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Tcr2 Therapeutics Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Tcr2 Therapeutics Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Beyond Meat To Launch Meatless Chicken Tenders at Grocery Stores in October
President Biden Hosting Leaders From India, Japan, Australia Friday in First 'Quad' Summit
Some Chinese Banks Stop Offering New Credit to Property Developers Amid Evergrande Scare
Iowa Senator Chuck Grassley Seeks Eighth Term of Office
House Select Committee Subpoenas Four Trump Allies in US Capitol Riot Probe
CDC Endorses COVID-19 Vaccine Booster Shots for Millions of Older and Vulnerable Individuals
Semiconductor Shortage To Cost Global Auto Industry $210 Billion in Revenue in 2021
US Olympic Athletes Must Have COVID-19 Vaccination for Beijing Winter Games



Market Movers

Sponsored Financial Content